GL1X · GenesisL1 explorer

MolNFT v1 · #436886 · protein

AlphaFold monomer V2.0 prediction for SERINE/ARGININE repetitive matrix protein 1 (Q8IYB3)

Q8IYB3: “AlphaFold monomer V2.0 prediction for SERINE/ARGININE repetitive matrix protein 1 (Q8IYB3)”. MolNFT v1 #436886 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

Accession
Q8IYB3
Type
protein
Length
904 residues
Chains
1
Collection
MolNFT v1 / AlphaFold
Contract
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
Owner
0x661f92Fc5950020C7aB410B5F5b9a3f429F49Ae5
Molecule
SERINE/ARGININE repetitive matrix protein 1
UniProt
Q8IYB3

Structure

1 distinct chain · 17% helix, 0% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ASERINE/ARGININE repetitive matrix protein 1protein90417% helix, 0% strandQ8IYB3

Compared structures

  • 7DVQ · Cryo-EM structure of the activated human minor spliceosome (minor bact complex) · an experimental structure of the same protein · chain A against 8, TM-score 0.13
  • 1MP1 · Solution structure of the PWI motif from SRm160 · an experimental structure of the same protein · chain A against A, TM-score 0.11
  • 1MP1 · Solution structure of the pwi motif from SRM160 · an experimental structure of the same protein · chain A against A, TM-score 0.11
  • 6FF4 · human Bact spliceosome core structure · an experimental structure of the same protein · chain A against Y, TM-score 0.10
  • 6FF4 · Human bact spliceosome core structure · an experimental structure of the same protein · chain A against Y, TM-score 0.10
  • 6FF7 · Human bact spliceosome core structure · an experimental structure of the same protein · chain A against Y, TM-score 0.10
  • 7ABH · Human pre-bact-2 spliceosome (SF3B/U2 snrnp portion) · an experimental structure of the same protein · chain A against Y, TM-score 0.10
  • 7ABI · Human pre-bact-2 spliceosome · an experimental structure of the same protein · chain A against Y, TM-score 0.10

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.